

Transmission of SARS-CoV-2 within Dutch households

No registrations found.

Ethical review	Positive opinion
Status	Recruitment stopped
Health condition type	-
Study type	Observational non invasive

Summary

ID

NL-OMON25872

Source

NTR

Brief title

FFX-COVID-19

Health condition

COVID-19, SARS-CoV-2

Sponsors and support

Primary sponsor: National Institute for Public Health and the Environment (RIVM)

Source(s) of monetary or material Support: National Institute for Public Health and the Environment (RIVM), Ministry of Health, Welfare and Sport

Intervention

Outcome measures

Primary outcome

To estimate secondary attack rates of SARS-CoV-2 and determine factors that impact susceptibility and infectiousness.

Secondary outcome

To determine the clinical presentation of COVID-19.

To determine the proportion of symptomatic and asymptomatic SARS-CoV-2 infections within households.

To determine the dynamics and the anatomical sites of virus replication in COVID-19 cases.

To determine immunological dynamics in COVID-19 cases.

To assess the serological and cellular immune response of COVID-19 cases.

Study description

Background summary

In December 2019 the first infections of SARS-CoV-2 (COVID-19 disease) were detected in Wuhan, China. The first COVID-19 case in the Netherlands was confirmed on February 27, 2020. In March 2020, the Dutch government mandated a partial lockdown, characterized by social distancing, self-quarantine, closing of schools, bars, and restaurants, and urging people to work from home. As household members live in close contact, the household constitutes a high risk setting for SARS-CoV-2 transmission. The main aims of the present study were to determine the important clinical, epidemiological, virological and immunological characteristics of first COVID-19 cases in the Netherlands and their household contacts. We wanted to estimate secondary attack rates of SARS-CoV-2 and to determine factors that impact susceptibility and infectiousness, stratified by the age of household contacts. We used a dense sampling strategy with sampling from various anatomical sites and by using several molecular and serological diagnostics methods to determine the presence of the SARS-CoV-2 virus.

Study objective

Secondary attack rates of SARS-CoV-2 will differ when stratified for the age of the index case.

Study design

T1: Home visit within 24 hours after positive test of index case. At this time point we collect questionnaire, serum, naso- and oropharyngeal swabs, saliva and feces.

T2: Home visit 2-3 weeks after inclusion. Data that are collected include questionnaire, serum, swabs, saliva and feces.

T3: Home visit 4-6 weeks after inclusion. Collection of questionnaire, serum, saliva and feces.

T4: Self sampling 6 months after inclusion. Serum by self-sampling (finger prick) and questionnaire.

T5: home visit 9-10 months after inclusion. To collect questionnaire, serum and saliva samples.

Intervention

Not applicable

Contacts

Public

National Institute for Public Health and the Environment (RIVM)
Inge Roof

+31629649396

Scientific

National Institute for Public Health and the Environment (RIVM)
Inge Roof

+31629649396

Eligibility criteria

Inclusion criteria

Any person 16 years and older testing positive for SARS-CoV-2 (index case) who had at least one child in their household below the age of 18 and consented to be contacted for scientific research. Every household contact (persons living in the same house as the index patient) was to be enrolled in the study.

Exclusion criteria

Household contacts below the age of 1. Households were excluded if one or more of the household contacts did not want to participate in the study upfront.

Study design

Design

Study type:	Observational non invasive
Intervention model:	Other
Allocation:	Non controlled trial
Masking:	Open (masking not used)
Control:	N/A , unknown

Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	23-03-2020
Enrollment:	250
Type:	Actual

IPD sharing statement

Plan to share IPD: Undecided

Ethics review

Positive opinion	
Date:	02-11-2021
Application type:	First submission

Study registrations

Followed up by the following (possibly more current) registration

ID: 54806
Bron: ToetsingOnline
Titel:

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL9850
CCMO	NL13529.041.06
OMON	NL-OMON54806

Study results

Summary results

<https://pubmed.ncbi.nlm.nih.gov/33822007/>